Hemab Therapeutics (COAG)
Market Price (9/11/2026): $39.93 | Market Cap: $1.2 BilSector: Health Care | Industry: Biotechnology
Hemab Therapeutics (COAG)
Market Price (9/11/2026): $39.93Market Cap: $1.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -52% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -82 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% Key risksCOAG key risks include [1] the potential failure of its novel and unproven product candidates to complete development and commercialization, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -38% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -52% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -82 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Key risksCOAG key risks include [1] the potential failure of its novel and unproven product candidates to complete development and commercialization, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/10/2026
Hemab Therapeutics (COAG) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Successful Initial Public Offering (IPO) and Bolstered Financial Runway.
Hemab Therapeutics completed an upsized initial public offering in May 2026, raising gross proceeds of $346.7 million and approximately $317.2 million in net proceeds. This significant capital infusion extended the company's cash, cash equivalents, and marketable securities runway into 2029, providing financial stability for ongoing and future clinical programs.
2. Positive Clinical Trial Data and FDA Endorsement for Lead Candidate, Sutacimig.
The company reported positive Phase 2 long-term extension (LTE) data for its lead candidate, sutacimig (HMB-001), demonstrating sustained bleed reduction and a manageable safety profile in Glanzmann thrombasthenia. Crucially, the U.S. Food and Drug Administration (FDA) endorsed the clinical data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with initiation planned for fiscal second half of 2026. This builds on the Breakthrough Therapy Designation granted for sutacimig in March 2026.
Show more
Hemab Therapeutics (COAG) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Successful Initial Public Offering (IPO) and Bolstered Financial Runway.
Hemab Therapeutics completed an upsized initial public offering in May 2026, raising gross proceeds of $346.7 million and approximately $317.2 million in net proceeds. This significant capital infusion extended the company's cash, cash equivalents, and marketable securities runway into 2029, providing financial stability for ongoing and future clinical programs.
2. Positive Clinical Trial Data and FDA Endorsement for Lead Candidate, Sutacimig.
The company reported positive Phase 2 long-term extension (LTE) data for its lead candidate, sutacimig (HMB-001), demonstrating sustained bleed reduction and a manageable safety profile in Glanzmann thrombasthenia. Crucially, the U.S. Food and Drug Administration (FDA) endorsed the clinical data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with initiation planned for fiscal second half of 2026. This builds on the Breakthrough Therapy Designation granted for sutacimig in March 2026.
Show more
Updated on 9/10/2026
Hemab Therapeutics (COAG) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Successful Initial Public Offering (IPO) and Bolstered Financial Runway.
Hemab Therapeutics completed an upsized initial public offering in May 2026, raising gross proceeds of $346.7 million and approximately $317.2 million in net proceeds. This significant capital infusion extended the company's cash, cash equivalents, and marketable securities runway into 2029, providing financial stability for ongoing and future clinical programs.
2. Positive Clinical Trial Data and FDA Endorsement for Lead Candidate, Sutacimig.
The company reported positive Phase 2 long-term extension (LTE) data for its lead candidate, sutacimig (HMB-001), demonstrating sustained bleed reduction and a manageable safety profile in Glanzmann thrombasthenia. Crucially, the U.S. Food and Drug Administration (FDA) endorsed the clinical data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with initiation planned for fiscal second half of 2026. This builds on the Breakthrough Therapy Designation granted for sutacimig in March 2026.
3. Promising Early Clinical Data for HMB-002 and Expansion of Pipeline with HMB-003.
Hemab Therapeutics presented new clinical data for HMB-002 in Von Willebrand Disease, showing a 2.4-fold increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), indicating a stronger-than-anticipated proof of mechanism. Furthermore, the company unveiled HMB-003, a novel peptide-based plasmin inhibitor aimed at reducing bleeding in conditions such as heavy menstrual bleeding, with first-in-human studies anticipated in fiscal second half of 2026. These developments highlight the breadth and potential of Hemab's pipeline.
4. Favorable Analyst Coverage and Increased Price Targets.
Following these corporate and clinical milestones, several investment analysts initiated or updated their coverage with positive ratings. Firms like Jefferies Financial Group, HC Wainwright, and Wedbush increased their price targets for COAG. For example, Jefferies raised its price objective from $39.00 to $47.00, HC Wainwright lifted its target from $52.00 to $60.00, and Wedbush boosted its target from $55.00 to $64.00, reflecting growing confidence in the company's prospects.
Show less
Hemab Therapeutics (COAG) stock has gained about 40% since 5/31/2026 because of the following key factors:
1. Successful Initial Public Offering (IPO) and Bolstered Financial Runway.
Hemab Therapeutics completed an upsized initial public offering in May 2026, raising gross proceeds of $346.7 million and approximately $317.2 million in net proceeds. This significant capital infusion extended the company's cash, cash equivalents, and marketable securities runway into 2029, providing financial stability for ongoing and future clinical programs.
2. Positive Clinical Trial Data and FDA Endorsement for Lead Candidate, Sutacimig.
The company reported positive Phase 2 long-term extension (LTE) data for its lead candidate, sutacimig (HMB-001), demonstrating sustained bleed reduction and a manageable safety profile in Glanzmann thrombasthenia. Crucially, the U.S. Food and Drug Administration (FDA) endorsed the clinical data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with initiation planned for fiscal second half of 2026. This builds on the Breakthrough Therapy Designation granted for sutacimig in March 2026.
3. Promising Early Clinical Data for HMB-002 and Expansion of Pipeline with HMB-003.
Hemab Therapeutics presented new clinical data for HMB-002 in Von Willebrand Disease, showing a 2.4-fold increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), indicating a stronger-than-anticipated proof of mechanism. Furthermore, the company unveiled HMB-003, a novel peptide-based plasmin inhibitor aimed at reducing bleeding in conditions such as heavy menstrual bleeding, with first-in-human studies anticipated in fiscal second half of 2026. These developments highlight the breadth and potential of Hemab's pipeline.
4. Favorable Analyst Coverage and Increased Price Targets.
Following these corporate and clinical milestones, several investment analysts initiated or updated their coverage with positive ratings. Firms like Jefferies Financial Group, HC Wainwright, and Wedbush increased their price targets for COAG. For example, Jefferies raised its price objective from $39.00 to $47.00, HC Wainwright lifted its target from $52.00 to $60.00, and Wedbush boosted its target from $55.00 to $64.00, reflecting growing confidence in the company's prospects.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 39.9% change in COAG stock from 5/31/2026 to 9/10/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9102026 | Change |
|---|---|---|---|
| Stock Price ($) | 28.50 | 39.88 | 39.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | � | 0.0% |
| Net Income Margin (%) | � | � | 0.0% |
| P/E Multiple | � | � | 0.0% |
| Shares Outstanding (Mil) | 27 | 27 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2026 to 9/10/2026| Return | Correlation | |
|---|---|---|
| COAG | 39.9% | |
| Market (SPY) | 0.2% | 21.3% |
| Sector (XLV) | 10.8% | -4.2% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 9/10/2026| Return | Correlation | |
|---|---|---|
| COAG | ||
| Market (SPY) | 10.8% | 21.2% |
| Sector (XLV) | 3.8% | -1.9% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/10/2026| Return | Correlation | |
|---|---|---|
| COAG | ||
| Market (SPY) | 18.5% | 21.2% |
| Sector (XLV) | 22.1% | -1.9% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/10/2026| Return | Correlation | |
|---|---|---|
| COAG | ||
| Market (SPY) | 74.2% | 21.2% |
| Sector (XLV) | 30.2% | -1.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COAG Return | - | - | - | - | - | 31% | 31% |
| Peers Return | 8% | 5% | -39% | 42% | 0% | 47% | 45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| COAG Win Rate | - | - | - | - | - | 40% | |
| Peers Win Rate | 50% | 47% | 22% | 42% | 43% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| COAG Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -30% | -30% | -52% | -37% | -40% | -38% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PFE, BMRN, QURE, CBIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/10/2026 (YTD)
How Low Can It Go
COAG has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
COAG has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Hemab Therapeutics (COAG)
Hemab Therapeutics (COAG) is a clinical-stage biotechnology company dedicated to developing innovative therapies for blood coagulation disorders. These conditions, which include serious bleeding and thrombotic diseases, often impose a significant lifelong burden on patients due to a lack of effective prophylactic treatments or limitations with current approaches. Hemab's core mission is to establish itself as a leader in the coagulation field by discovering, developing, and commercializing new medicines.
The company's primary product candidates target specific coagulation disorders with high unmet needs. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, conditions affecting an estimated 10,000 patients globally. Hemab's second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 development for the subcutaneous prophylactic treatment of Von Willebrand Disease, a condition estimated to affect 120,000 patients. The company also maintains a pipeline of preclinical and discovery-stage assets.
Hemab aims to establish a leading coagulation franchise through its "Hemab 2x3 by 2030" strategic roadmap, targeting two commercial medicines, two new late-stage, and two new early-stage clinical programs by 2030. The primary customers are patients suffering from these rare coagulation disorders, and the company intends to commercialize its assets in key geographies including the United States, the European Union, Japan, the Gulf Cooperation Council countries, and other select regions, believing the addressable patient population could expand with increased awareness and new treatment options.
AI Analysis | Feedback
Here are a few analogies to describe Hemab Therapeutics (COAG):
Vertex Pharmaceuticals for blood coagulation disorders.
Intuitive Surgical for blood coagulation therapies.
AI Analysis | Feedback
- sutacimig (HMB-001): A bispecific antibody currently in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
- HMB-002: A monovalent antibody in clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease.
AI Analysis | Feedback
Hemab Therapeutics (COAG) is a clinical-stage biotechnology company. As described in the background information, the company's product candidates are currently in Phase 1/2 and Phase 2 clinical development and have not yet received regulatory approval or been commercialized. Therefore, Hemab Therapeutics does not currently have major customers, as it is not selling any products.
AI Analysis | Feedback
null
AI Analysis | Feedback
Benny Sorensen, MD, PhD, Chief Executive Officer
Benny Sorensen co-founded Hemab Therapeutics in 2020. He joined Hemab as CEO from Codiak Biosciences, where he served as Senior Vice President, Strategic Projects, and was involved in building the company and advancing its first engineered exosome therapeutics from idea to clinical proof of concept. Prior to Codiak, he was Senior Director of Clinical Research at Alnylam Pharmaceuticals, leading the development of fitusiran and other hematology products. He also served as a Global Medical Director at Baxter Healthcare Corporation, advancing the pivotal development of Adynovate® and Vonvendi®. Hemab has secured funding from private equity firms such as Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity.
Mads Behrndt, Chief Financial Officer
Mads Behrndt was appointed Chief Financial Officer of Hemab in September 2021. He brings over 14 years of financial experience in international capital markets and business development. Before joining Hemab, he was a Partner at PwC's Corporate Finance team, where he led and executed private and public company financings and M&A transactions. Hemab is backed by a syndicate of top-tier investors.
Kate Madigan, MD, Chief Medical Officer
Kate Madigan was appointed Chief Medical Officer of Hemab in January 2025. Previously, she served as Chief Medical Officer at Syndax Pharmaceuticals, where she led the U.S. Food and Drug Administration (FDA) approvals of Revuforj and Niktimvo. Her extensive leadership experience also includes roles as Senior Medical Director at Alnylam Pharmaceuticals and Medical Director within Biogen's Rare Disease Innovation Unit.
Anant Murthy, PhD, Chief Operating Officer
Anant Murthy was appointed Chief Operating Officer of Hemab in September 2025. In this role, he is responsible for leading the company's global efforts in market access, launch, and commercialization of Hemab's pipeline.
Caroline Rasmussen, DVM, PhD, Vice President, Nonclinical Development
Caroline Rasmussen serves as Vice President, Nonclinical Development at Hemab, bringing over a decade of experience in nonclinical development, from early drug development to marketing authorization. She began her career at Novo Nordisk A/S, focusing primarily on the hemostasis portfolio. Most recently, she was Director of Toxicology and Safety Pharmacology at Ascendis Pharma A/S.
Benny Sorensen co-founded Hemab Therapeutics in 2020. He joined Hemab as CEO from Codiak Biosciences, where he served as Senior Vice President, Strategic Projects, and was involved in building the company and advancing its first engineered exosome therapeutics from idea to clinical proof of concept. Prior to Codiak, he was Senior Director of Clinical Research at Alnylam Pharmaceuticals, leading the development of fitusiran and other hematology products. He also served as a Global Medical Director at Baxter Healthcare Corporation, advancing the pivotal development of Adynovate® and Vonvendi®. Hemab has secured funding from private equity firms such as Novo Holdings, HealthCap, RA Capital Management, Access Biotechnology, Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity.
Mads Behrndt, Chief Financial Officer
Mads Behrndt was appointed Chief Financial Officer of Hemab in September 2021. He brings over 14 years of financial experience in international capital markets and business development. Before joining Hemab, he was a Partner at PwC's Corporate Finance team, where he led and executed private and public company financings and M&A transactions. Hemab is backed by a syndicate of top-tier investors.
Kate Madigan, MD, Chief Medical Officer
Kate Madigan was appointed Chief Medical Officer of Hemab in January 2025. Previously, she served as Chief Medical Officer at Syndax Pharmaceuticals, where she led the U.S. Food and Drug Administration (FDA) approvals of Revuforj and Niktimvo. Her extensive leadership experience also includes roles as Senior Medical Director at Alnylam Pharmaceuticals and Medical Director within Biogen's Rare Disease Innovation Unit.
Anant Murthy, PhD, Chief Operating Officer
Anant Murthy was appointed Chief Operating Officer of Hemab in September 2025. In this role, he is responsible for leading the company's global efforts in market access, launch, and commercialization of Hemab's pipeline.
Caroline Rasmussen, DVM, PhD, Vice President, Nonclinical Development
Caroline Rasmussen serves as Vice President, Nonclinical Development at Hemab, bringing over a decade of experience in nonclinical development, from early drug development to marketing authorization. She began her career at Novo Nordisk A/S, focusing primarily on the hemostasis portfolio. Most recently, she was Director of Toxicology and Safety Pharmacology at Ascendis Pharma A/S.
AI Analysis | Feedback
The key risks for Hemab Therapeutics (COAG) are:
- The risk that its novel and unproven product candidates may not successfully complete clinical development, receive regulatory approval, or be effectively commercialized. This is due to the early stage of development, the lack of established prophylactic therapies to inform endpoint selection and trial design, and the inherent uncertainties of clinical trials.
- The risk of failing to achieve its strategic goals outlined in the "Hemab 2x3 by 2030" roadmap, which aims to build a franchise consisting of two commercial medicines, two new late-stage clinical programs, and two new early-stage clinical programs by 2030.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for Hemab Therapeutics' main products are:
- Glanzmann thrombasthenia and Factor VII deficiency: approximately 10,000 patients. This market size is for the United States, the European Union, Japan, the Gulf Cooperation Council countries, and other select regions.
- Von Willebrand Disease: approximately 120,000 patients. This market size is for the United States, the European Union, Japan, the Gulf Cooperation Council countries, and other select regions.
AI Analysis | Feedback
Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. As a pre-revenue company, its future revenue growth over the next two to three years will be primarily driven by the successful advancement and potential commercialization of its pipeline assets.
The key expected drivers of future revenue growth for Hemab Therapeutics include:
- Successful progression of sutacimig (HMB-001) through late-stage clinical trials for Glanzmann thrombasthenia and Factor VII deficiency. sutacimig is the company's lead asset, poised to enter a Phase 3 clinical trial for Glanzmann thrombasthenia in the second half of 2026. It is being developed as the first prophylactic treatment for Glanzmann thrombasthenia, a severe bleeding disorder. Additionally, Phase 2 clinical data for sutacimig in Factor VII deficiency is anticipated in late 2026 or early 2027. Positive outcomes from these trials are crucial steps toward regulatory approval and eventual commercial launch.
- Advancement of HMB-002 into late-stage clinical development for Von Willebrand Disease. HMB-002, a monovalent antibody, is currently in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease, the most common inherited bleeding disorder. Hemab aims to advance HMB-002 towards a registration study. Successful progression through clinical development for this asset could unlock access to a significantly larger patient population and represent a substantial future revenue stream.
- Expansion of the pipeline with new clinical-stage assets, such as HMB-003. Hemab's strategic roadmap, "Hemab 2x3 by 2030," includes building a franchise with two new early-stage clinical programs by 2030. The company expects to announce HMB-003, another novel drug candidate, in the first half of 2026. The successful advancement of these new programs into clinical development could broaden Hemab's portfolio and establish additional platforms for future revenue generation, potentially through milestone payments from partnerships or eventual product commercialization.
AI Analysis | Feedback
Share Repurchases
Hemab Therapeutics has not reported any share repurchases for the trailing twelve months ending December 2025, with a reported value of $0.00 million. As a recently public, clinical-stage biotechnology company, it has not engaged in share buyback programs.
Share Issuance
- Hemab Therapeutics completed its Initial Public Offering (IPO) on May 1, 2026, raising $302 million by offering 16.8 million shares at $18 per share.
- The IPO was upsized to 16.75 million shares and priced at $18.00 per share, raising $301.5 million.
- The underwriters fully exercised their option to purchase an additional 2,512,500 shares, bringing the total shares issued in the IPO to 19,262,500 at $18.00 per share.
Inbound Investments
- In October 2025, Hemab Therapeutics closed a $157 million Series C financing round, led by Sofinnova Partners with participation from new and existing investors including Novo Holdings, RA Capital Management, and Avoro Capital Advisors.
- The company secured a $135 million Series B financing round in 2023, with participation from investors such as Novo Holdings.
- Hemab Therapeutics raised $55 million in a Series A financing round in 2021, co-led by Novo Holdings.
Capital Expenditures
- Hemab Therapeutics reported minimal capital expenditures, with -$0.02 million for the year ending December 2025 and -$0.28 million for December 2024.
Peer Outperformance in Biotechnology
nullShare of Biotechnology constituents that COAG has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
—
insufficient peer history
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is COAG's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.1% | 85.2% | 140.0% | CAH 398% · MCK 345% · COR 176% |
| Managed Health Care | 8 | 43.5% | -2.0% | 7.1% | OSCR 86% · HQY 48% · ELV 25% |
| Health Care Services | 20 | 17.8% | 48.3% | -2.1% | HIMS 215% · RDNT 153% · DGX 64% |
| Health Care Facilities | 24 | 4.1% | 4.3% | -16.8% | NHC 267% · THC 262% · ENSG 118% |
| Health Care Equipment | 50 | -2.8% | -7.2% | -27.0% | POCI 10875% · UFPT 317% · GKOS 225% |
| Health Care Supplies | 12 | 21.1% | -13.9% | -37.7% | LNTH 287% · HAE 50% · MMSI 21% |
| Pharmaceuticals | 62 | -5.7% | 2.2% | -40.8% | LQDA 2394% · INDV 1137% · ETON 1055% |
| Life Sciences Tools & Services | 109 | -0.2% | -31.5% | -71.6% | SNWV 1533% · MEDP 204% · NTRA 171% |
| Biotechnology ← | 362 | 0.3% | -24.9% | -78.1% | DNTH 1516% · CELZ 1257% · ELVN 1178% |
| Health Care Technology | 20 | -24.8% | -54.6% | -79.3% | SPOK 77% · HSTM -2% · VEEV -14% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 39.88 |
| Mkt Cap | 2.9 |
| Rev LTM | 19 |
| Op Inc LTM | -82 |
| FCF LTM | -73 |
| FCF 3Y Avg | 543 |
| CFO LTM | -73 |
| CFO 3Y Avg | 651 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.2% |
| Rev Chg 3Y Avg | -5.2% |
| Rev Chg Q | 11.0% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Inc Chg LTM | -15.8% |
| Op Inc Chg 3Y Avg | 80.3% |
| Op Mgn LTM | -506.4% |
| Op Mgn 3Y Avg | 13.8% |
| QoQ Delta Op Mgn LTM | -2.9% |
| CFO/Rev LTM | -295.3% |
| CFO/Rev 3Y Avg | 19.7% |
| FCF/Rev LTM | -423.9% |
| FCF/Rev 3Y Avg | 15.1% |
Price Behavior
null
COAG Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.91 | 0.92 | 1.28 | 0.42 | 0.65 | -0.79 |
| Up Beta | -0.94 | -0.25 | 2.36 | -1.01 | -1.82 | 1.54 |
| Down Beta | 9.69 | 2.87 | 1.73 | -2.33 | -1.48 | 1.12 |
| Up Capture | 53% | 233% | 203% | 112% | 51% | 5% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 12 | 27 | 38 | 46 | 46 | 46 |
| Down Capture | 193% | -71% | -47% | 67% | 42% | 23% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 9 | 15 | 25 | 36 | 36 | 36 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COAG | |
|---|---|---|---|---|
| COAG | 17.4% | 94.7% | 0.91 | - |
| Sector ETF (XLV) | 21.2% | 16.2% | 1.00 | -1.9% |
| Equity (SPY) | 17.6% | 12.8% | 0.99 | 21.2% |
| Gold (GLD) | 18.7% | 29.2% | 0.59 | 23.3% |
| Commodities (DBC) | 47.9% | 20.4% | 1.81 | -17.7% |
| Real Estate (VNQ) | 6.6% | 13.6% | 0.22 | 4.1% |
| Bitcoin (BTCUSD) | -29.9% | 43.8% | -0.68 | -4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COAG | |
|---|---|---|---|---|
| COAG | 3.2% | 94.7% | 0.91 | - |
| Sector ETF (XLV) | 5.8% | 15.2% | 0.20 | -1.9% |
| Equity (SPY) | 12.4% | 17.2% | 0.55 | 21.2% |
| Gold (GLD) | 18.5% | 18.8% | 0.80 | 23.3% |
| Commodities (DBC) | 11.5% | 19.5% | 0.46 | -17.7% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 4.1% |
| Bitcoin (BTCUSD) | 9.9% | 52.6% | 0.37 | -4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COAG | |
|---|---|---|---|---|
| COAG | 1.6% | 94.7% | 0.91 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | -1.9% |
| Equity (SPY) | 15.1% | 17.9% | 0.71 | 21.2% |
| Gold (GLD) | 12.2% | 16.3% | 0.61 | 23.3% |
| Commodities (DBC) | 8.4% | 18.1% | 0.38 | -17.7% |
| Real Estate (VNQ) | 4.6% | 20.7% | 0.19 | 4.1% |
| Bitcoin (BTCUSD) | 63.4% | 66.2% | 1.03 | -4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Recent Forward Guidance
Updated 8/12/2026Latest: Q2 2026 Earnings Reported 8/11/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Reported | |||||||
Insider Activity
Updated 6/17/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ra, Capital Management, LP | See footnotes | Buy | 6172026 | 24.98 | 61,523 | 1,536,845 | 160,987,032 | Form | |
| 2 | Ra, Capital Management, LP | See footnotes | Buy | 6172026 | 24.89 | 6,146 | 152,974 | 158,875,707 | Form | |
| 3 | Ra, Capital Management, LP | See footnotes | Buy | 5212026 | 24.94 | 996 | 24,840 | 159,041,582 | Form | |
| 4 | Ra, Capital Management, LP | See footnotes | Buy | 5212026 | 24.97 | 3,802 | 94,936 | 159,208,021 | Form | |
| 5 | Ra, Capital Management, LP | See footnotes | Buy | 5142026 | 24.90 | 6,387 | 159,036 | 158,667,033 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ra, Capital Management, LP | See footnotes | Buy | 6172026 | 24.98 | 61,523 | 1,536,845 | 160,987,032 | Form | |
| 2 | Ra, Capital Management, LP | See footnotes | Buy | 6172026 | 24.89 | 6,146 | 152,974 | 158,875,707 | Form | |
| 3 | Ra, Capital Management, LP | See footnotes | Buy | 5212026 | 24.94 | 996 | 24,840 | 159,041,582 | Form | |
| 4 | Ra, Capital Management, LP | See footnotes | Buy | 5212026 | 24.97 | 3,802 | 94,936 | 159,208,021 | Form | |
| 5 | Ra, Capital Management, LP | See footnotes | Buy | 5142026 | 24.90 | 6,387 | 159,036 | 158,667,033 | Form | |
| 6 | Ra, Capital Management, LP | See footnotes | Buy | 5112026 | 24.81 | 39,869 | 989,226 | 157,947,233 | Form | |
| 7 | Ra, Capital Management, LP | See footnotes | Buy | 5112026 | 24.98 | 1,483 | 37,045 | 158,021,332 | Form | |
| 8 | Ra, Capital Management, LP | See footnotes | Buy | 5112026 | 24.46 | 9,906 | 242,323 | 154,709,711 | Form | |
| 9 | Ra, Capital Management, LP | See footnotes | Buy | 5062026 | 24.60 | 68,018 | 1,673,399 | 155,351,842 | Form | |
| 10 | Ra, Capital Management, LP | See footnotes | Buy | 5062026 | 24.63 | 97,411 | 2,399,546 | 153,871,567 | Form | |
| 11 | Ra, Capital Management, LP | See footnotes | Buy | 5062026 | 18.00 | 2,675,000 | 48,150,000 | 110,683,728 | Form |
Hemab Therapeutics — Investor Video Playlist
Investor / Analyst
Building a Franchise: Hemab’s Strategic Progress in 2025
Products & Services
Early Clinical Wins: HMB-002’s Promise for Von Willebrand Disease
Products & Services
Sutacimig’s (HMB-001) Journey: Milestones, Data, and Progress
Products & Services
Breakthrough Non-Hormonal Option for Heavy Menstrual Bleeding
Products & Services
Hemab’s Revolutionary Approach to Clotting Disorders
Investor / Analyst
Beyond Single Diseases: Hemab's Multi-Indication Drug Pipeline
Leadership
Hemab Advances HMB-001 for Rare Bleeding Disorders
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/10/2026